06.06.12

pSivida Corp. Announces Issuance of US Patent for Inserter to Be Used in Planned Phase 3 Uveitis Trials

Source: pSivida Corp.
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases,  announced it has been issued US patent No. 8,192,408 titled “Ocular Trocar Assembly” for a new inserter developed to facilitate administration of micro-drug delivery devices.

“We are very pleased with the issuance of this US patent for our new inserter,” said Dr. Paul Ashton, president and CEO of pSivida. “We have designed it to allow the insertion of drug delivery devices, such as our Medidur implant, through a far smaller needle than was previously possible and to require significantly less force to administer. We anticipate using this new inserter in the planned phase 3 trials of our posterior uveitis insert.

“Another advantage,” Dr. Ashton continued, “is that the new inserter allows for use of larger reservoir delivery devices. Thus our Durasert technology can now be used with a larger number of drugs.”

pSivida has a very strong intellectual property portfolio with more than 100 granted patents in the US, Europe, Japan, China and Australia.

Related Content